Vaxcellbio Partners with Reber Genetics to Expand Companion Animal Immunotherapy in Asia

Strategic Deal Targets Regional Growth 

Vaxcellbio, an immuno-oncology company led by CEO Je-Jung Lee, has signed a master partnership agreement with Taiwan-based Reber Genetics, an animal vaccine developer and distributor. The deal aims to expand immune-based healthcare products for companion animals across Asia. 

According to Towards Healthcare, the companion animal genetics market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 5.4 billion in 2026 to approximately USD 12.59 billion by 2035, representing a compound annual growth rate (CAGR) of 9.85% from 2026 to 2035, driven by rising pet ownership, increasing awareness of genetic diseases, advancements in diagnostics, and growing demand for personalized veterinary care. 

Framework for Technology Transfer and Approvals 

The agreement sets a clear framework for technology transfer, product export, and supply between the two companies. Both firms will work together to secure regulatory approvals and launch products in Taiwan, Thailand, and Vietnam. Vaxcellbio will provide its technologies and product pipeline, while Reber Genetics will handle local approvals, distribution, and commercialization. 

Key Products to Lead Expansion 

The partners plan to transfer technology for Vaxleukin-15, an immune-based therapy for companion animals. They will also promote Goldmmune, an immune supplement, and Vaxsure, another immune-based healthcare product. This move is expected to speed up Vaxcellbio’s expansion into overseas markets. 

Mutual Benefits and Future Plans 

Reber Genetics brings strong experience in genetic and immune-based animal healthcare, along with a wide distribution network across Asia. Through this partnership, it will expand its product portfolio, while Vaxcellbio will use Reber’s local expertise to grow its presence in regional markets. 

CEO Je-Jung Lee said the agreement will strengthen the company’s position in companion animal immunotherapy and support global growth. Chairman Sunny Kang added that the collaboration will introduce new healthcare solutions to Asian markets. 

Vaxcellbio plans to sign further agreements in phases to boost its global footprint and improve access to advanced animal healthcare. The partnership reflects rising demand for veterinary care in Asia, driven by increasing pet ownership and interest in advanced treatments. The companies will begin operations in Taiwan before expanding gradually into other markets. 

A recent report by Towards Healthcare highlights that the companion animal genetics market is witnessing growth due to expanding research investments, improved testing technologies, supportive regulations, and increasing adoption of genetic screening among veterinarians and pet owners globally.